DE602006008781D1 - Festphasengebundenes thymosin-alpha1 und dessen synthese - Google Patents

Festphasengebundenes thymosin-alpha1 und dessen synthese

Info

Publication number
DE602006008781D1
DE602006008781D1 DE602006008781T DE602006008781T DE602006008781D1 DE 602006008781 D1 DE602006008781 D1 DE 602006008781D1 DE 602006008781 T DE602006008781 T DE 602006008781T DE 602006008781 T DE602006008781 T DE 602006008781T DE 602006008781 D1 DE602006008781 D1 DE 602006008781D1
Authority
DE
Germany
Prior art keywords
solid phase
alpha1
synthesis
thymosine
bonded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006008781T
Other languages
English (en)
Inventor
Fernando Albericio
Luis Javier Cruz
Ramos Yesica Garcia
Judit Tulla-Puche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Publication of DE602006008781D1 publication Critical patent/DE602006008781D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57581Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602006008781T 2005-05-04 2006-05-04 Festphasengebundenes thymosin-alpha1 und dessen synthese Active DE602006008781D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05009758 2005-05-04
US69985105P 2005-07-18 2005-07-18
PCT/EP2006/004192 WO2006117227A2 (en) 2005-05-04 2006-05-04 Solid phase bound thymosin alpha-1 and its synthesis

Publications (1)

Publication Number Publication Date
DE602006008781D1 true DE602006008781D1 (de) 2009-10-08

Family

ID=36650882

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006008781T Active DE602006008781D1 (de) 2005-05-04 2006-05-04 Festphasengebundenes thymosin-alpha1 und dessen synthese

Country Status (17)

Country Link
US (1) US20090171068A1 (de)
EP (1) EP1891104B1 (de)
JP (1) JP2008543733A (de)
KR (1) KR20080012884A (de)
CN (1) CN101166761A (de)
AT (1) ATE440856T1 (de)
AU (1) AU2006243344B2 (de)
CA (1) CA2600303A1 (de)
DE (1) DE602006008781D1 (de)
DK (1) DK1891104T3 (de)
ES (1) ES2332666T3 (de)
IL (1) IL186774A0 (de)
MX (1) MX2007013400A (de)
NO (1) NO20074623L (de)
PT (1) PT1891104E (de)
WO (1) WO2006117227A2 (de)
ZA (1) ZA200708110B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US20090149673A1 (en) * 2007-12-05 2009-06-11 Semprus Biosciences Corp. Synthetic non-fouling amino acids
CN103242443A (zh) * 2012-02-06 2013-08-14 长春百克生物科技股份公司 一种胸腺素α1及其类似物的制备方法
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
CN107001409A (zh) * 2014-09-26 2017-08-01 株式会社钟化 疏水性肽的制造方法
CN104327181A (zh) * 2014-09-28 2015-02-04 上海昂博生物技术有限公司 固相合成胸腺肽α1
CN108239147B (zh) * 2016-12-27 2023-11-10 江苏豪森药业集团有限公司 胸腺素α1衍生物的制备方法
CN111349152B (zh) * 2018-12-20 2022-04-05 深圳翰宇药业股份有限公司 一种制备胸腺法新的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341935B1 (de) * 1988-05-10 1996-04-10 Alpha-1 Biomedicals, Inc. Festphase-Verfahren zur Gewinnung von Thymosin-alpha-1
US6262230B1 (en) * 1994-01-28 2001-07-17 Sciclone Pharmaceuticals Inc. Analogs of thymosin α1
US6204360B1 (en) * 1999-12-16 2001-03-20 Usa Universe Bioengineering, Inc. Retro-inverso thymosin alpha 1 hybrids
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物

Also Published As

Publication number Publication date
CN101166761A (zh) 2008-04-23
EP1891104B1 (de) 2009-08-26
PT1891104E (pt) 2009-12-07
KR20080012884A (ko) 2008-02-12
IL186774A0 (en) 2008-02-09
WO2006117227A2 (en) 2006-11-09
ZA200708110B (en) 2008-10-29
CA2600303A1 (en) 2006-11-09
ATE440856T1 (de) 2009-09-15
WO2006117227A3 (en) 2007-03-15
US20090171068A1 (en) 2009-07-02
EP1891104A2 (de) 2008-02-27
NO20074623L (no) 2007-12-03
ES2332666T3 (es) 2010-02-10
JP2008543733A (ja) 2008-12-04
MX2007013400A (es) 2008-04-29
DK1891104T3 (da) 2009-11-30
AU2006243344B2 (en) 2011-04-21
AU2006243344A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
DE602006008781D1 (de) Festphasengebundenes thymosin-alpha1 und dessen synthese
NO20071309L (no) Fremgangsmate for ekspansjon
ATE486853T1 (de) Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten
FR2883179B1 (fr) Comprime enrobe
BRPI0814995A2 (pt) Métodos para a síntese de olefinas e derivados
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
ES2380489T8 (es) Proceso para la síntesis de compuestos orgánicos
CR10256A (es) Soporte estructural
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
ATE507215T1 (de) Verbesserte synthese und zubereitungen von duloxetinsalzen
DK1781618T3 (da) Sigma-receptorinhibitorer
ATE500249T1 (de) Synthese von himbacinanaloga
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
DE602005024305D1 (de) Verfahren zu synthese von glycolonitril
NO20065231L (no) Nye imidazoler
DE602005004685D1 (de) Tonwellenform Synthesizer
UY30801A1 (es) Compuestos calciliticos
ATE390411T1 (de) Stereoselektive synthese von vitamin-d-analoga
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
ATE524167T1 (de) Transdermales pflaster
ATE459627T1 (de) Synthesen und herstellungen von narwedin und verwandten neuen verbindungen
JP2007063161A5 (ja) 急性相反応タンパク質転写抑制剤
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
DE602007000376D1 (de) Katalytisches Eintopfverfahren zur Synthese von Isocyanaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition